The most frequent cancer diagnosis and one of the major causes of mortality worldwide is lung cancer. The reactions from Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) Current outcomes for Non-Small Cell Lung Cancer (NSCLC) patients treated with standard chemo- and radiotherapies remain unsatisfactory. New developments in DNA sequencing technology have just begun to take off, offering promising methods for researching various malignancies for methodical mutation detection. There have only been a few DDR inhibition trials for the treatment of SCLC and NSCLC patients to date. However, methods to test various DDR inhibitor combinations or to focus on numerous pathways have not yet been investigated. Future trials should be planned to enable the study of targeted treatments in a biomarker-enriched population, which is justifiable for the improvement of prognosis for SCLC and NSCLC patients, in light of the various biomarkers that have either recently been discovered or are the subject of ongoing investigations.
